Zacharis, Aristeidis
Reimold, Philipp
Aksoy, Cem
Jung, Jonas
Martin, Thomas
Eisenmenger, Nicole
Thoduka, Smita George
Groeben, Christer
Huber, Johannes
Flegar, Luka http://orcid.org/0000-0002-1477-9161
Funding for this research was provided by:
Philipps-Universität Marburg
Article History
Received: 31 July 2023
Accepted: 13 November 2023
First Online: 10 January 2024
Declarations
:
: Mrs. Eisenmenger is founder and director of RI Innovation GmbH. J. Huber is Medical Board member of the "Urologische Stiftung Gesundheit gGmbH," Chairman of the Working Group "Health Services Research, Quality and Economics" of the German Society of Urology e. V. and initiator of the "Entscheidungshilfe Prostatakrebs" (ExternalRef removed). The latter is supported by Takeda Pharma, Janssen Cilag GmbH and Apogepha. Further he indicates support of scientific projects outside the submitted work by Intuitive Surgical and Coloplast. Luka Flegar is a consultant for BK Medical. All the other authors have no conflicts of interest to declare.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethics approval was not required.
: Not applicable.